These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 8733411)
1. Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya. van Gorkom J; Kibuga DK Tuber Lung Dis; 1996 Feb; 77(1):30-6. PubMed ID: 8733411 [TBL] [Abstract][Full Text] [Related]
2. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Hawken M; Nunn P; Gathua S; Brindle R; Godfrey-Faussett P; Githui W; Odhiambo J; Batchelor B; Gilks C; Morris J Lancet; 1993 Aug; 342(8867):332-7. PubMed ID: 7687729 [TBL] [Abstract][Full Text] [Related]
3. Adverse cutaneous reactions to thiacetazone for tuberculosis treatment in Tanzania. Ipuge YA; Rieder HL; Enarson DA Lancet; 1995 Sep; 346(8976):657-60. PubMed ID: 7544858 [TBL] [Abstract][Full Text] [Related]
4. Life-threatening cutaneous reactions to thiacetazone-containing antituberculosis treatment in Kumasi, Ghana. Lawn SD; Frimpong EH; Acheampong JW West Afr J Med; 1999; 18(4):249-53. PubMed ID: 10734785 [TBL] [Abstract][Full Text] [Related]
5. Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection. Elliott AM; Foster SD Tuber Lung Dis; 1996 Feb; 77(1):27-9. PubMed ID: 8733410 [No Abstract] [Full Text] [Related]
6. Cutaneous reactions to thiacetazone in Zambia--implications for tuberculosis treatment strategies. Kelly P; Buve A; Foster SD; McKenna M; Donnelly M; Sipatunyana G Trans R Soc Trop Med Hyg; 1994; 88(1):113-5. PubMed ID: 7512287 [TBL] [Abstract][Full Text] [Related]
7. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults. Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099 [TBL] [Abstract][Full Text] [Related]
8. Cutaneous hypersensitivity reactions to thiacetazone, HIV infection and thiacetazone concentrations in plasma. Watkins WM; Mungai M; Muhia DK; Mberu EK; Gathua S; Winstanley PA; Gilks CF; Nunn P Br J Clin Pharmacol; 1996 Feb; 41(2):160-2. PubMed ID: 8838444 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania. Sweat M; Gregorich S; Sangiwa G; Furlonge C; Balmer D; Kamenga C; Grinstead O; Coates T Lancet; 2000 Jul; 356(9224):113-21. PubMed ID: 10963247 [TBL] [Abstract][Full Text] [Related]
10. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon. Kuaban C; Bercion R; Koulla-Shiro S East Afr Med J; 1997 Aug; 74(8):474-7. PubMed ID: 9487410 [TBL] [Abstract][Full Text] [Related]
11. The influence of HIV status on single and multiple drug reactions to antituberculous therapy in Africa. Pozniak AL; MacLeod GA; Mahari M; Legg W; Weinberg J AIDS; 1992 Aug; 6(8):809-14. PubMed ID: 1384557 [TBL] [Abstract][Full Text] [Related]
12. Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-I. Chintu C; Luo C; Bhat G; Raviglione M; DuPont H; Zumla A Arch Dis Child; 1993 May; 68(5):665-8. PubMed ID: 7686737 [TBL] [Abstract][Full Text] [Related]
13. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. Nunn P; Brindle R; Carpenter L; Odhiambo J; Wasunna K; Newnham R; Githui W; Gathua S; Omwega M; McAdam K Am Rev Respir Dis; 1992 Oct; 146(4):849-54. PubMed ID: 1416409 [TBL] [Abstract][Full Text] [Related]
14. Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania. Dukes CS; Sugarman J; Cegielski JP; Lallinger GJ; Mwakyusa DH Trop Geogr Med; 1992 Oct; 44(4):308-11. PubMed ID: 1284179 [TBL] [Abstract][Full Text] [Related]
15. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration. Okwera A; Whalen C; Byekwaso F; Vjecha M; Johnson J; Huebner R; Mugerwa R; Ellner J Lancet; 1994 Nov; 344(8933):1323-8. PubMed ID: 7526098 [TBL] [Abstract][Full Text] [Related]
16. Aspects of tuberculosis in Africa. 2. The value of microbiology in the management of tuberculosis in Nairobi, Kenya. Brindle R Trans R Soc Trop Med Hyg; 1992; 86(5):470-1. PubMed ID: 1475805 [TBL] [Abstract][Full Text] [Related]
17. Use of thiacetazone. Foster S; Kelly P Lancet; 1995 Jan; 345(8941):62-3. PubMed ID: 7528311 [No Abstract] [Full Text] [Related]
18. Further consequences of thioacetazone-induced cutaneous reactions. Lawn SD; Griffin GE Int J Tuberc Lung Dis; 2000 Jan; 4(1):92-3. PubMed ID: 10654652 [No Abstract] [Full Text] [Related]
19. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. Currie CS; Floyd K; Williams BG; Dye C BMC Public Health; 2005 Dec; 5():130. PubMed ID: 16343345 [TBL] [Abstract][Full Text] [Related]